vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $104.0M, roughly 1.6× Origin Bancorp, Inc.). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 3.9%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
ESPR vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $104.0M |
| Net Profit | — | $27.7M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 26.6% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $168.4M | $103.4M | ||
| Q3 25 | $87.3M | $109.8M | ||
| Q2 25 | $82.4M | $83.5M | ||
| Q1 25 | $65.0M | $94.1M | ||
| Q4 24 | $69.1M | $78.3M | ||
| Q3 24 | $51.6M | $90.8M | ||
| Q2 24 | $73.8M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | — | $29.5M | ||
| Q3 25 | $-31.3M | $8.6M | ||
| Q2 25 | $-12.7M | $14.6M | ||
| Q1 25 | $-40.5M | $22.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $-29.5M | $18.6M | ||
| Q2 24 | $-61.9M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 36.2% | ||
| Q3 25 | -11.4% | 10.0% | ||
| Q2 25 | 8.6% | 22.3% | ||
| Q1 25 | -34.0% | 30.4% | ||
| Q4 24 | -6.4% | 23.0% | ||
| Q3 24 | -31.0% | 26.1% | ||
| Q2 24 | 3.5% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | — | 28.5% | ||
| Q3 25 | -35.9% | 7.9% | ||
| Q2 25 | -15.4% | 17.5% | ||
| Q1 25 | -62.2% | 23.8% | ||
| Q4 24 | — | 18.2% | ||
| Q3 24 | -57.2% | 20.5% | ||
| Q2 24 | -83.9% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $0.32 | $0.95 | ||
| Q3 25 | $-0.16 | $0.27 | ||
| Q2 25 | $-0.06 | $0.47 | ||
| Q1 25 | $-0.21 | $0.71 | ||
| Q4 24 | $-0.14 | $0.45 | ||
| Q3 24 | $-0.15 | $0.60 | ||
| Q2 24 | $-0.33 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.3B |
| Total Assets | $465.9M | $10.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | $424.2M | ||
| Q3 25 | $92.4M | $626.9M | ||
| Q2 25 | $86.1M | $334.1M | ||
| Q1 25 | $114.6M | $486.2M | ||
| Q4 24 | $144.8M | $470.2M | ||
| Q3 24 | $144.7M | $321.2M | ||
| Q2 24 | $189.3M | $288.1M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $-302.0M | $1.2B | ||
| Q3 25 | $-451.4M | $1.2B | ||
| Q2 25 | $-433.5M | $1.2B | ||
| Q1 25 | $-426.2M | $1.2B | ||
| Q4 24 | $-388.7M | $1.1B | ||
| Q3 24 | $-370.2M | $1.1B | ||
| Q2 24 | $-344.2M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $465.9M | $9.7B | ||
| Q3 25 | $364.0M | $9.8B | ||
| Q2 25 | $347.1M | $9.7B | ||
| Q1 25 | $324.0M | $9.8B | ||
| Q4 24 | $343.8M | $9.7B | ||
| Q3 24 | $314.1M | $10.0B | ||
| Q2 24 | $352.3M | $9.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $158.9M | ||
| Q3 25 | $-4.3M | $59.3M | ||
| Q2 25 | $-31.4M | $20.6M | ||
| Q1 25 | $-22.6M | $35.6M | ||
| Q4 24 | $-35.0M | $108.5M | ||
| Q3 24 | $-35.3M | $39.6M | ||
| Q2 24 | $-7.2M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $151.1M | ||
| Q3 25 | — | $56.8M | ||
| Q2 25 | — | $19.6M | ||
| Q1 25 | — | $34.8M | ||
| Q4 24 | — | $86.4M | ||
| Q3 24 | $-35.5M | $32.2M | ||
| Q2 24 | $-7.3M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 51.7% | ||
| Q2 25 | — | 23.5% | ||
| Q1 25 | — | 37.0% | ||
| Q4 24 | — | 110.3% | ||
| Q3 24 | -68.7% | 35.5% | ||
| Q2 24 | -9.9% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 7.6% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 28.1% | ||
| Q3 24 | 0.3% | 8.1% | ||
| Q2 24 | 0.1% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | — | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
